Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.5574 -0.0326 (-5.53%)
Streaming Delayed Price Updated: 12:10 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vbi Vaccines Inc CS

< Previous 1 2 3 4 Next >
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
From VBI Vaccines Inc.
Via Business Wire
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the Jefferies Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.